Romano (DeMuro) CD, Lewis S, Barrett A, Andersson FL, Williams V, Ancoli-Israel S, Roth T. Development of the Nocturia Sleep Quality Scale: a patient-reported outcome measure of sleep impact related to nocturia. Sleep Med. 2019 Jul;59:101-6. doi: 10.1016/j.sleep.2019.02.006
Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care. BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x
Khan AM, Trope GE, Wedge R, Buys YM, El-Defrawy S, Chen Q, Jin YP. Policy implications of regional variations in eye disease detection and treatment on Prince Edward Island: a repeated cross-sectional analysis, 2010-2012. BMC Health Serv Res. 2018 Apr 10;18(1):273. doi: 10.1186/s12913-018-3068-z
Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of sleep apnoea: a systematic review and meta-analysis. Sleep Med. 2018 Feb;42:38-46. doi: 10.1016/j.sleep.2017.12.005.
Nickel KB, Wallace AE, Warren DK, Ball KE, Mines D, Fraser VJ, Olsen MA. Modification of claims-based measures improves identification of comorbidities in non-elderly women undergoing mastectomy for breast cancer: a retrospective cohort study. BMC Health Serv Res. 2016 Aug 16;16(a):388. doi: 10.1186/s12913-016-1636-7
Karve SJ, Price GL, Davis KL, Pohl GM, Smyth E, Bowman L. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res. 2014 Nov 13;14(1):555. doi: 10.1186/s12913-014-0555-8
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Small N, Bower P, Chew-Graham CA, Whalley D, Protheroe J. Patient empowerment in long-term conditions: development and preliminary testing of a new measure. BMC Health Serv Res. 2013 Jul 8;13:Article N.
Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res. 2012 Jan 24;12:20. doi: 10.1186/1472-6963-12-20
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin SA. Measurement properties of the medical outcomes study sleep scale in patients with fibromyalgia. Sleep Med. 2009 Aug;10(7):766-70.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
McCrink L, Allen RP, Wolowacz SE, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med. 2007 Jan 1;8(1):73-83.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.